The added value of type I interferons to cytotoxic treatments of cancer

Research output: Contribution to journalShort survey

6 Citations (Scopus)

Abstract

Type I interferons (IFNs) exert anti-proliferative, antiviral and immunomodulatory activities. They are also involved in cell differentiation and anti-tumor defense processes. A growing body of literature indicates that the success of conventional chemotherapeutics, epigenetic drugs, targeted anticancer agents and radiotherapy (RT) relies, at least in part, on the induction of type I IFN signaling in malignant cells, tumor-infiltrating antigen presenting cells or other immune cells within lymphoid organs or blood. The mechanisms underlying type I IFN induction and the clinical consequences of these observations are only beginning to be elucidated. In the present manuscript, we reviewed the recent advances in the field and provided our personal view on the role of type I IFNs induced in the context of cytotoxic anticancer treatments and on its possible exploitation as a complement in cancer therapy.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalCytokine and Growth Factor Reviews
Volume36
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Interferon Type I
Neoplasms
Manuscripts
Radiotherapy
Neoplasm Antigens
Antigen-Presenting Cells
Therapeutics
Epigenomics
Antineoplastic Agents
Antiviral Agents
Tumors
Cell Differentiation
Blood
Lymphocytes
Pharmaceutical Preparations

Keywords

  • Chemotherapy
  • Immunogenicity
  • Radiotherapy
  • Type I interferon

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The added value of type I interferons to cytotoxic treatments of cancer. / Bracci, Laura; Sistigu, Antonella; Proietti, Enrico; Moschella, Federica.

In: Cytokine and Growth Factor Reviews, Vol. 36, 01.08.2017, p. 89-97.

Research output: Contribution to journalShort survey

@article{ee3e698bb2c94ef5b62648a710edf9a9,
title = "The added value of type I interferons to cytotoxic treatments of cancer",
abstract = "Type I interferons (IFNs) exert anti-proliferative, antiviral and immunomodulatory activities. They are also involved in cell differentiation and anti-tumor defense processes. A growing body of literature indicates that the success of conventional chemotherapeutics, epigenetic drugs, targeted anticancer agents and radiotherapy (RT) relies, at least in part, on the induction of type I IFN signaling in malignant cells, tumor-infiltrating antigen presenting cells or other immune cells within lymphoid organs or blood. The mechanisms underlying type I IFN induction and the clinical consequences of these observations are only beginning to be elucidated. In the present manuscript, we reviewed the recent advances in the field and provided our personal view on the role of type I IFNs induced in the context of cytotoxic anticancer treatments and on its possible exploitation as a complement in cancer therapy.",
keywords = "Chemotherapy, Immunogenicity, Radiotherapy, Type I interferon",
author = "Laura Bracci and Antonella Sistigu and Enrico Proietti and Federica Moschella",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.cytogfr.2017.06.008",
language = "English",
volume = "36",
pages = "89--97",
journal = "Cytokine and Growth Factor Reviews",
issn = "1359-6101",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The added value of type I interferons to cytotoxic treatments of cancer

AU - Bracci, Laura

AU - Sistigu, Antonella

AU - Proietti, Enrico

AU - Moschella, Federica

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Type I interferons (IFNs) exert anti-proliferative, antiviral and immunomodulatory activities. They are also involved in cell differentiation and anti-tumor defense processes. A growing body of literature indicates that the success of conventional chemotherapeutics, epigenetic drugs, targeted anticancer agents and radiotherapy (RT) relies, at least in part, on the induction of type I IFN signaling in malignant cells, tumor-infiltrating antigen presenting cells or other immune cells within lymphoid organs or blood. The mechanisms underlying type I IFN induction and the clinical consequences of these observations are only beginning to be elucidated. In the present manuscript, we reviewed the recent advances in the field and provided our personal view on the role of type I IFNs induced in the context of cytotoxic anticancer treatments and on its possible exploitation as a complement in cancer therapy.

AB - Type I interferons (IFNs) exert anti-proliferative, antiviral and immunomodulatory activities. They are also involved in cell differentiation and anti-tumor defense processes. A growing body of literature indicates that the success of conventional chemotherapeutics, epigenetic drugs, targeted anticancer agents and radiotherapy (RT) relies, at least in part, on the induction of type I IFN signaling in malignant cells, tumor-infiltrating antigen presenting cells or other immune cells within lymphoid organs or blood. The mechanisms underlying type I IFN induction and the clinical consequences of these observations are only beginning to be elucidated. In the present manuscript, we reviewed the recent advances in the field and provided our personal view on the role of type I IFNs induced in the context of cytotoxic anticancer treatments and on its possible exploitation as a complement in cancer therapy.

KW - Chemotherapy

KW - Immunogenicity

KW - Radiotherapy

KW - Type I interferon

UR - http://www.scopus.com/inward/record.url?scp=85021700370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021700370&partnerID=8YFLogxK

U2 - 10.1016/j.cytogfr.2017.06.008

DO - 10.1016/j.cytogfr.2017.06.008

M3 - Short survey

VL - 36

SP - 89

EP - 97

JO - Cytokine and Growth Factor Reviews

JF - Cytokine and Growth Factor Reviews

SN - 1359-6101

ER -